| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 46 | 24.1x | 17.8x | Around median | |
Growth | 31 | 8.5% | 7.1% | Bottom tier | |
Quality | 72 | 10.1% | 4.5% | Top tier | |
Safety | 90 | 0.3x | 2.6x | Top tier | |
Capital Return | 19 | 0.28% | 2.12% | Bottom tier | |
Momentum | 71 | 53.4% | 2.9% | Top tier | |
Sentiment | 24 | 1 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
CTS Corporation manufactures high-value sensing and actuation technologies, components, and subsystems for the medical, industrial, aerospace and defense, and transportation markets. Its applications include diagnostic imaging, therapies, and minimally invasive procedures; automation and communications infrastructure; naval sonar and secure communications; as well as vehicle sensors and foot controls. In fiscal 2026 Q2, diversified end markets accounted for 59% of sales, compared with 55% a year earlier, while transportation represented the remaining 41%.
Fiscal 2026 Q2 revenue was approximately $144.8 million, up 7% year over year and 4% from the previous quarter. Diversified market sales increased 15%, while transportation sales declined 2%; the company achieved a record adjusted gross margin of 41.5% and an adjusted EBITDA margin of 25.4%, with record adjusted diluted earnings per share of $0.74. Foreign exchange gains and a significant customer reimbursement contributed approximately $0.07 to earnings per share, meaning that part of the result was not fully recurring operationally.
For the trailing twelve months through fiscal 2026, CTS recorded revenue of $554.8 million, gross profit of $216.5 million, and net income of $69.1 million, with earnings per share of approximately $2.38. In fiscal 2026 Q2, medical led the growth mix with revenue of $28 million and growth of 45%, industrial revenue reached $40 million with growth of 16%, while aerospace and defense recorded $18 million, down 15%, and transportation recorded $59 million, down 2%.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus rating on CTS stock is Neutral, and the provided data does not support a consensus price target or a high-to-low target range that could be used as an additional anchor. The 52-week range extends from $36.03 to $69.55, while no reported price-to-earnings ratio is available; therefore, the valuation assessment depends on the company's ability to convert its fiscal 2026 guidance and $1.2 billion in booked business into recurring growth without relying on foreign exchange gains or unusual customer reimbursements.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Revenue increased 7% to $144.8 million, driven by 15% growth in diversified markets despite a 2% decline in transportation. Medical was the fastest-growing driver, with revenue jumping 45% to $28 million, while industrial grew 16% to $40 million. The improved mix and operational execution resulted in a record adjusted gross margin of 41.5% and adjusted diluted earnings per share of $0.74, although approximately $0.07 of that came from foreign exchange and a customer reimbursement.
The medical business generated revenue of $28 million in fiscal 2026 Q2, up 45% annually and 14% from the previous quarter. The book-to-bill ratio was 1.21, indicating continued customer demand for sensing and actuation technologies. CTS products are used in diagnostic imaging, therapies, and minimally invasive procedures, and the production capacity required to increase therapy application volumes had already been installed.
In fiscal 2026 Q2, CTS secured approximately $163 million in new transportation business awards from manufacturers in North America, Japan, China, and Europe. The awards included a contract worth nearly $100 million for an integrated application combining wheel-speed and acceleration sensing, a record amount for the company's sensor portfolio. CTS also added a new North American electric-vehicle customer for a seat-track position sensor, but the timing of the conversion of these awards into revenue was not specified on the call.
Management raised its fiscal 2026 revenue forecast to a range of between $565 million and $585 million. It also raised the adjusted diluted earnings per share range to $2.55–$2.70. The guidance assumes continued growth in medical, industrial, and aerospace and defense, against global light-vehicle production ranging from flat to slightly lower, while the outcomes of pricing negotiations and tariff and metal costs remain uncertain.
In fiscal 2026 Q2, the company generated operating cash flow of $33 million, with capital expenditures of $4.6 million and free cash flow of approximately $29 million. Cash at the end of the quarter was $108 million against borrowings of $55 million. CTS repurchased approximately 64 thousand shares for $3.5 million, with $78 million remaining available under the repurchase program.
The transportation business faces expectations for flat or slightly lower light-vehicle production, alongside the continued transition by Cummins to a second sourcing supplier and uncertainty about the final competitive share until near the end of fiscal 2026. Aerospace and defense revenue also declined 15% to $18 million in fiscal 2026 Q2 because of the timing of funding and government contracts. The company is also monitoring Section 301 tariffs, precious-metals inflation, input costs, and USMCA negotiations, while new transportation program launches may pressure margins in their early stages.
